COVID Variant BA.3.2 'Cicada' Spreads to 25 US States

A newly identified and heavily mutated COVID-19 variant is drawing serious attention from health officials and researchers across the globe. Known formally as BA.3.2 and nicknamed 'Cicada' by scientists, this emerging strain has now been detected in 25 U.S. states and 23 countries — and a landmark CDC Morbidity and Mortality Weekly Report published on March 25, 2026 has triggered a wave of public concern. With approximately 70–75 mutations in its spike protein, BA.3.2 carries more changes than most variants seen in recent years, raising legitimate questions about how well existing vaccines and prior immunity can keep it at bay. Here is everything you need to know.

What Is the BA.3.2 'Cicada' COVID Variant?

BA.3.2 is a descendant of the Omicron family, specifically branching off from the JN.1 lineage. It was first identified in November 2024 in a respiratory sample collected in South Africa. Its first confirmed U.S. appearance came on June 27, 2025, when surveillance detected it in a traveler arriving from the Netherlands at San Francisco International Airport.

The variant earned its 'Cicada' nickname because, much like the insect, it appeared to remain dormant after initial detection — only to re-emerge and spread more widely months later. According to Everyday Health, researchers noted this unusual pattern of quiet circulation followed by a more aggressive spread, which made early tracking difficult.

What sets BA.3.2 apart is the sheer volume of mutations in its spike protein. While previous notable variants carried dozens of changes, BA.3.2 carries approximately 70 to 75 spike protein mutations compared to the JN.1-lineage viruses targeted by current COVID-19 vaccines. This mutation load is what scientists say may allow it to partially evade both vaccine-induced and infection-acquired immunity.

How Widespread Is BA.3.2 in the United States?

The CDC's March 2026 report formally documented the scope of BA.3.2's spread across the country, drawing on multiple surveillance channels:

• 132 wastewater samples collected across 25 states
• Nasal swabs from 4 international travelers
• 3 airplane wastewater samples
• Clinical samples from 5 patients

The confirmed states include major population centers such as California, New York, Texas, Florida, Illinois, and Pennsylvania, as well as detections across both urban and rural communities in other states. A full tracker of U.S. states with confirmed detections shows the geographic reach of the variant continues to expand.

Despite these detections, it is important to keep the numbers in perspective. BA.3.2 currently represents only about 0.19 percent of roughly 2,500 total genetic sequences analyzed in U.S. national surveillance. That means it remains a small fraction of COVID-19 cases — but one that health officials are watching closely given its rate of growth.

How Is It Spreading Globally?

BA.3.2's international footprint is broader than its U.S. numbers might suggest. As of February 11, 2026, the variant had been confirmed in 23 countries. Europe has seen some of the highest concentrations, with BA.3.2 accounting for 30 percent of samples collected in Denmark, Germany, and the Netherlands between November 2025 and January 2026 — a striking share that signals the variant's competitive advantage over other circulating strains in those regions.

The variant has also continued evolving. Scientists have already identified two sublineages — BA.3.2.1 and BA.3.2.2 — indicating that BA.3.2 is actively mutating as it spreads. Experts note that ongoing evolution in a highly mutated variant warrants close monitoring, as further changes could affect transmissibility, immune evasion, or disease severity.

What Are the Symptoms of BA.3.2?

Based on current clinical reports, the symptoms of BA.3.2 appear broadly similar to those of other recent COVID-19 variants. Reported symptoms include:

• Cough
• Fever
• Fatigue
• Headache
• Sore throat (notably severe in some cases)
• Body aches
• Sneezing
• Nasal congestion

A severe sore throat has been flagged as a commonly reported symptom among BA.3.2 cases, which mirrors patterns seen with some earlier Omicron subvariants. There is currently no evidence that BA.3.2 causes more severe lower respiratory illness, hospitalization, or death at higher rates than other circulating strains. Neither the CDC nor the WHO has raised its threat level based on severity data.

Should You Be Worried About Vaccine Effectiveness?

The question of vaccine protection against BA.3.2 is where much of the scientific concern is concentrated. Current COVID-19 vaccines — including updated formulations — were designed to target JN.1-lineage viruses. Because BA.3.2 carries 70–75 changes in the very spike protein that vaccines train the immune system to recognize, there is a reasonable concern that vaccine-induced antibodies may be less effective at neutralizing this variant.

However, this does not mean vaccines are useless. Immunologists consistently emphasize that vaccines provide multiple layers of protection — including T-cell responses that target conserved parts of the virus not exclusively tied to spike protein recognition. These deeper immune responses tend to be more durable and cross-reactive across variants.

Health officials and researchers are assessing whether a BA.3.2-targeted vaccine update may be needed for future formulations. For now, staying up to date with currently available vaccines — particularly for high-risk individuals — remains the best available protection against severe illness, even if neutralizing antibody responses may be somewhat reduced.

What Health Officials Are Saying

The CDC's formal documentation of BA.3.2 in its Morbidity and Mortality Weekly Report signals that the agency is treating this as a variant requiring active surveillance, even if it has not yet declared an elevated public health emergency. Officials describe the current threat level as low but evolving, pointing to the relatively small share of total U.S. COVID-19 sequences the variant represents at this stage.

At the same time, the phrase "viral evolution" has featured prominently in official communications, reflecting concern that BA.3.2's mutation profile and international spread pattern could position it to drive a new wave — potentially a summer surge — if it gains further competitive advantage over currently dominant strains. The CDC's wastewater surveillance network, which detected BA.3.2 across 132 samples in 25 states, continues to serve as an early warning system for any acceleration in spread.

The WHO has also been monitoring BA.3.2 globally, and its classification in coming weeks — whether as a Variant Under Monitoring, Variant of Interest, or a higher designation — will offer another signal of how seriously international health authorities view its trajectory.

Frequently Asked Questions About BA.3.2 'Cicada'

Is BA.3.2 more dangerous than previous COVID variants?

Not based on current evidence. Neither the CDC nor the WHO has reported data showing that BA.3.2 causes more severe illness, higher hospitalization rates, or increased mortality compared to other circulating strains. The primary concern is its potential for immune evasion due to its large number of spike protein mutations.

Which states have confirmed BA.3.2 cases?

As of the CDC's March 25, 2026 report, BA.3.2 has been detected in 25 U.S. states, including California, New York, Texas, Florida, Illinois, and Pennsylvania, among others. Detections have occurred in both urban and rural communities through wastewater surveillance and clinical samples.

Do current COVID-19 vaccines protect against BA.3.2?

Current vaccines may offer reduced neutralizing antibody protection against BA.3.2 due to its extensive spike protein mutations. However, they are still expected to provide meaningful protection against severe disease through T-cell immunity and other immune mechanisms. Staying up to date on vaccinations remains important, especially for vulnerable populations.

How did BA.3.2 get the nickname 'Cicada'?

Researchers nicknamed it 'Cicada' because after its initial detection in South Africa in November 2024, the variant appeared to remain quiet — much like a cicada staying dormant underground — before re-emerging and spreading more broadly, particularly in Europe and the United States starting in mid-2025.

What should I do if I think I have BA.3.2?

Symptoms of BA.3.2 are similar to other COVID-19 strains, so standard guidance applies: test if you have symptoms, isolate if positive, and seek medical care if your symptoms are severe or you are in a high-risk group. Antiviral treatments such as Paxlovid, if prescribed promptly, are expected to remain relevant as they target parts of the virus beyond the spike protein.

Conclusion

BA.3.2 'Cicada' is a legitimate subject of scientific concern — not because it is causing mass severe illness right now, but because its unprecedented spike protein mutation load and confirmed international spread raise real questions about how the virus continues to outpace immunity. With 25 U.S. states, 23 countries, and two already-identified sublineages, the variant's trajectory is worth following closely.

For now, the message from health officials is measured: stay informed, stay vaccinated, and monitor for updates from the CDC and WHO as surveillance data evolves. BA.3.2 has earned scientific attention — and the 'Cicada' name may prove apt if it emerges this summer with the same surprise as its insect namesake. Keeping an eye on developments from trusted health sources will be the most important step any individual can take in the weeks ahead.